Our Team.

Daniel F. Hoth, MD, is a medical oncologist with more than thirty years’ experience in clinical development of investigational drugs in cancer and infectious disease. Previously, he served at the National Cancer Institute as Chief of the Investigational Drug Branch where he was responsible for all clinical investigations of IND stage anticancer pharmaceuticals. Subsequently, he was Director of the Division of AIDS at the National Institute of Allergy and Infectious Disease. Later, he served as Senior Vice President and Chief Medical Officer of Axys Pharmaceuticals, as well as Senior Vice President and Chief Medical Officer at Cell Genesys. He received his MD from Georgetown University School of Medicine.

Dr. Hoth currently consults on clinical development strategy to biotech, pharmaceutical, and academic institutions. His experience includes multiple clinical/scientific advisory boards, as well as the board of directors of several companies. He has advised or developed dozens of clinical development programs in oncology. Recently, he was acting Chief Medical Officer at QED (a BridgeBio subsidiary). He currently serves on the BridgeBio Clinical Advisory Board. He was also acting Chief Medical Officer at Aduro. He has advised the California Institute of Regenerative Medicine.

Dr. Hoth has participated in five NDAs. He has experience developing small molecules, antibodies, cytokines, gene therapies, and vaccines. He also has served as a consultant to both the FDA and NIH in oncology drug development. In addition, he has taught oncology drug development at UCSF.